Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024)
Antimicrobial Agents and Chemotherapy · 07.05.2025 · 69 (5)
DOI: 10.1128/aac.01867-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.05.2025. Verfasst von Aliaa Fouad und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Anti-Bacterial Agents, Ceftibuten. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Themen: Langzeitpflege
Abstract (Originalsprache)
Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates ( n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
- Department of Pathology, Division of Clinical Pathology, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
- Department of Pathology, Saint Louis University, St. Louis, Missouri, USA.
- Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Pathology, Harbor-UCLA Medical Center, Torrance, California, USA.
- Department of Pathology and Laboratory Medicine, Dartmouth Health, Lebanon, New Hampshire, USA.
ORCID-Profile: Aliaa Fouad, Holly K Huse, Isabella W Martin, David P Nicolau, Tomefa E Asempa
Förderung
- Pfizer
Zitieren
APA
Fouad, A., Bobenchik, A. M., Chamberland, R., Clark, A. E., Huse, H. K., Martin, I. W., Mochon, A. B., Munson, E., Sfeir, M. M., Srodon, M., Taylor, K., Wang, Y., Westblade, L. F., Nicolau, D. P., & Asempa, T. E. (2025). Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024). Antimicrobial Agents and Chemotherapy, 69(5). https://doi.org/10.1128/aac.01867-24
Vancouver
Fouad A, Bobenchik AM, Chamberland R, Clark AE, Huse HK, Martin IW, et al. Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024). Antimicrobial Agents and Chemotherapy. 2025;69(5). doi:10.1128/aac.01867-24
BibTeX
@article{Fouad2025,
author = {Fouad, Aliaa and Bobenchik, April M and Chamberland, Robin and Clark, Andrew E and Huse, Holly K and Martin, Isabella W and Mochon, A Brian and Munson, Erik and Sfeir, Maroun M and Srodon, Monica and Taylor, Kimberly and Wang, Yungchou and Westblade, Lars F and Nicolau, David P and Asempa, Tomefa E},
title = {Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024)},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {5},
doi = {10.1128/aac.01867-24}
}
EUVIMED